Teva Pharmaceutical/TEVA

$13.30

-4.1%
-
1D1W1MYTD1YMAX

About Teva Pharmaceutical

Teva Pharmaceutical Industries Ltd is a Israeli-based pharmaceutical company. The Company operates through three segments: North America, Europe and International Markets. Each business segment manages entire product portfolio in its region, including generics, specialty and over-the-counter (OTC) products. In addition to these three segments, The Company has other activities, primarily the sale of active pharmaceutical ingredients (API) to third parties, certain contract manufacturing services and an out-licensing platform offering a portfolio of products to other pharmaceutical companies through its affiliate Medis.

Ticker

TEVA

Sector

Healthcare

Trading on

NYSE

Industry

Biotechnology & Drugs

CEO

Richard Francis

Employees

35,001

Headquarters

Tel aviv-yafo, Israel

TEVA Metrics

BasicAdvanced
$15.62B
Market cap
-
P/E ratio
-$0.50
EPS
1.07
Beta
-
Dividend rate
$15.62B
1.06703
$14.47
$7.09
10.41M
1.02
0.691
241.953
264.229
3,650.155
3.55%
-1.41%
-7.3%
-1.98%
0.986
1.986
18.556
6.16%
77.27%
-1.65%

What the Analysts think about TEVA

Analyst Ratings

Majority rating from 14 analysts.
Buy

Price Targets

Average projection from 8 analysts.
16.54% upside
High $19.00
Low $9.00
$13.30
Current price
$15.50
Average price target

TEVA Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
9.62% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$4.46B
15.77%
Net income
$429M
443.04%
Profit margin
9.62%
369.27%

TEVA Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 30.29%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
$0.40
$0.56
$0.60
$1.00
-
Expected
$0.56
$0.53
$0.61
$0.77
$0.52
Surprise
-28.14%
6.64%
-1.38%
30.29%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
ADR

Upcoming events

FAQs

What’s the current market cap for Teva Pharmaceutical stock?

Teva Pharmaceutical (TEVA) has a market cap of $15.62B as of April 14, 2024.

What is the P/E ratio for Teva Pharmaceutical stock?

The price to earnings (P/E) ratio for Teva Pharmaceutical (TEVA) stock is 0 as of April 14, 2024.

Does Teva Pharmaceutical stock pay dividends?

No, Teva Pharmaceutical (TEVA) stock does not pay dividends to its shareholders as of April 14, 2024.

When is the next Teva Pharmaceutical dividend payment date?

Teva Pharmaceutical (TEVA) stock does not pay dividends to its shareholders.

What is the beta indicator for Teva Pharmaceutical?

Teva Pharmaceutical (TEVA) has a beta rating of 1.07. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the Teva Pharmaceutical stock price target?

The target price for Teva Pharmaceutical (TEVA) stock is $15.5, which is 16.54% above the current price of $13.3. This is an average based on projections from 8 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Teva Pharmaceutical stock

Buy or sell Teva Pharmaceutical stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing